I n mammals, JNKs (c-Jun N-terminal kinases) are encoded by three different genes (jnk1, jnk2, and jnk3) that are alternatively spliced to produce a total of approximately 10 different isoforms. The predominant genes jnk1 and jnk2 are expressed ubiquitously, while jnk3 is mainly expressed in neuronal tissues, the testes, and to a lesser extent in cardiac myocytes. 1 As a member of the mitogen-activated protein kinase (MAPK) family, JNKs regulate various cellular functions. 2 Hyperactivation of JNK occurs in a number of disease states, including type I and type II diabetes, Alzheimer's disease, arthritis, asthma, atherogenesis, heart failure, and Parkinson's disease. 3 Cellular stressors, including cytokines, hypoxia, UV light, and osmotic stress, stimulate JNK activity, leading to pro-inflammatory, mitogenic, or apoptotic signals, 4 which may contribute to the oncogenic functions of JNK. 5 JNK1 plays an important role in human hepatocellular carcinoma 6 and accelerates the development of chronic colitisinduced colorectal cancer. 7 Moreover, the JNK pathway is implicated in PI3K-driven human prostate cancer, where PTEN is often found inactivated, leading to increased AKT activity and elevated JNK activation, which in turn contributes to tumor cell proliferation and angiogenesis. 8 However, JNK1 is also reported to act as a tumor suppressor in DMBA/TPA-induced skin tumors and in spontaneous colon cancer, highlighting the complexities of JNK signaling. 9, 10 JNK2 is constitutively activated in glial tumor cell lines 11 and human glioblastoma models 12 and is implicated in the activation of Akt and overexpression of eukaryotic translation initiation factor 4 (eIF4E). 12 Interestingly, both JNK1 and JNK2 reportedly regulate cell migration, 13 and JNK2 has been shown to promote mammary cancer cell migration by specifically altering both the expression and trafficking of epidermal growth factor substrate 8 (EPS8) as well as its critical protein binding interactions, which connect growth factor signaling to the actin cytoskeleton during cell migration.
14 Cell migration is an essential process associated with tissue repair and regeneration, atherosclerosis, arthritis, mental retardation, embryonic morphogenesis, and cancer metastasis. 15 Recently we reported the design of peptide inhibitors that selectively targeted the protein-binding site of the JNK2 isoform and efficiently inhibit breast cancer cell migration. 16 Taken together, this reveals the importance of the JNKs as attractive targets for the treatment of a variety of diseases, especially cancer. However, no inhibitors of JNK have been approved for use in humans. 17 JNKs are mainly activated by phosphorylation of the activation loop at a Thr-Pro-Tyr (TPY) motif by the MAP2Ks MKK4 and MKK7 18 and are deactivated by MAPK phosphatases including MKP1 and MKP5. The JNK2 isoform is uniquely autophosphorylated without the requirement of MKK4 and MKK7. 19 Scaffolding proteins such as JIP 20 and arrestin 21 can assemble signaling complexes consisting of a MAP3K, a MAP2K, and a MAPK to promote specific JNKs.
Unlike ATP-competitive inhibitors, non-canonical inhibitors targeting protein interaction sites of JNK may disrupt the binding of JNK to upstream and downstream proteins, including phosphatases and scaffolds, resulting in the alteration of JNK signaling in cells. An important advantage of such non-ATP competitive inhibitors is that they do not have to compete with an intracellular ligand that is present at high millimolar concentrations, such as ATP. In addition, inhibitors that target protein binding sites may be uniquely specific for JNK. 22 Some trials have been conducted to discover small molecules targeting the protein-binding site of JNK. In 2008, Stebbins et al. discovered that the thiadiazole BI-78D3 (the first small molecule targeting the JNK-JIP interaction) 23 efficiently displaces biotinylated pepJIP1 from GST-JNK1 with an IC 50 of 500 nM. Additional reports have focused on the development of BI-78D3 and the enhancement of its plasma stability, 22 while others still continue the search for different scaffolds or peptides that act as inhibitors of the JNK-protein interaction. 22, 24 The largely solvent-exposed and relatively shallow protein docking sites of JNK 25 make the discovery and design of potent non-canonical inhibitors targeting the protein binding sites of MAP kinases difficult. Recently, we attempted to overcome this challenge by employing computational studies. Using virtual screening, a group of inhibitors targeting the JNK-JIP binding site was discovered. 26 One of these inhibitors, known as (−)-zuonin A (1, Scheme 1), selectively inhibits JNK over ERK2 and p38 MAPK. (−)-Zuonin A (1) is a 2,5-diaryl-3,4-dimethyltetrahydrofuranoid lignan which has been isolated from Aristolochia chilensis, 27 Saururus cernuus, 28 Piper schmidtii, 29 Chamaecyparis obtusa var. formosana, 30 and Piper f utokadsura. 31 Notably, two recent reports have implicated other lignan derivatives as having biological effects resulting from their activity toward MAP kinases. For example, saucerneol F, a tetrahydrofuran-type sesquilignan isolated from Saururus chinensis, inhibits nitric oxide (NO) production in a dose-dependent manner. This effect is accompanied by reduction of the inducible nitric oxide synthase (iNOS) protein and mRNA expression in lipopolysaccharide (LPS)-stimulated murine macrophage (RAW264.7) cells. Saucerneol F was reported to attenuate NO production and iNOS expression by blocking LPS-induced activation of NF-κB (NF-kappaB), AP-1, and most MAP kinases (including ERK1/2, p38 MAPK, and JNK). 32 Zuonin B, a stereoisomer of zuonin A, isolated from the flower buds of Daphne genkwa, is reported to exhibit immunological effects in RAW264.7 cells due to its ability to suppress the levels of nitric oxide, prostaglandin E 2 , and proinflammatory cytokines such as tumor necrosis factor-α and interleukin-6. The detailed study of its molecular mechanism demonstrated its ability to reduce NF-κB activation by suppressing proteolysis of IκBα and p65 nuclear translocation, as well as by inhibiting the phosphorylation of ERK 1/2 and JNK. 33 On the basis of these data saucerneol F and zuonin B have been proposed to be anti-inflammatory agents. It remains to be established whether they directly bind and inhibit MAPKs.
Here we describe the asymmetric synthesis of the lignans (−)-zuonin A and (+)-zuonin A and report both biochemical and biological approaches employed to show that (−)-zuonin A is an inhibitor of JNK. We identified two mechanisms as likely contributors to its ability to inhibit JNK signaling in cells.
■ RESULTS AND DISCUSSION
Synthesis of (−)-Zuonin A and (+)-Zuonin A. Recently, (−)-zuonin A (1, Scheme 1) was identified as an inhibitor of JNK following a virtual screening analysis designed to identify small molecule inhibitors of JNK-protein interactions. 26 While there are several reports of its isolation and structure determination in the literature, 27−31 its synthesis has not been reported. In addition, the absolute configuration of (−)-zuonin A (1) has not been established. Therefore, as part of an ongoing effort to characterize bioactive lignans we embarked on the total synthesis of (−)-zuonin A (1), drawing on our recent synthesis of substituted tetrahydrofurans. 34, 35 To this end we report a synthetic route that affords (−)-zuonin A (1) and its enantiomer (+)-zuonin A (2). As a result, the absolute configuration of (−)-zuonin A (1) and (+)-zuonin A (2) is now assigned.
Synthesis of Intermediate 7. The first stages of the synthesis involve the preparation of the chiral dihydrofuranone 7 (Scheme 1), which was accomplished following previously reported procedures. 34 Thus, commercially available (4S)-4-(1-methylethyl)-3-(1-oxopropyl)-2-oxazolidinone 3 was reacted with piperonal in the presence of n-Bu 2 BOTf and Et 3 N to provide the desired syn-adol adduct 4 in 78% yield as a single diastereomer. 36 Protection of 4 with TBSCl (90%) followed by LiBH 4 reduction (79%) provided the corresponding alcohol 5. Protection of 5 with MsCl and subsequent treatment with NaCN accomplished one-carbon homologation to give 6 (97% for two steps). TBS deprotection by TBAF, hydrolysis of the nitrile group to the corresponding carboxylic acid, and acidcatalyzed lactonization provided 7 in 91% for three steps.
Elaboration of 1 from 7. As demonstrated in the stereoselective synthesis of manassantins A and B, we envisioned that the installation of a sterically less demanding exo-methylene group as a precursor to the C4 methyl group would direct the addition of 11 via the "inside attack" model to provide the desired 2,3-cis-2,5-trans-tetrahydrofuran 12.
35
Alkylation of 7 with Eschenmoser's salt and m-CPBA oxidation smoothly proceeded to afford 8 in 95% for two steps. 37, 38 Reduction of 8 with DIBALH followed by treatment with PhSO 2 H provided 2-benzenesulfonyl cyclic ether 10. As expected, the exo-methylene group in 10 directed the addition of 11 to provide the desired 2,3-cis-2,5-trans-tetrahydrofuran 12 as a single diastereomer (76%). As demonstrated in the synthesis of manassantins A and B, 35 catalytic hydrogenation under conventional conditions (H 2 , Pd/C, EtOAc/MeOH) completed the asymmetric synthesis of 1 (38%, dr = 5:1, 97.7% ee). It should be noted that the double bond isomerization occurred during the catalytic hydrogenation reaction to give 13 (28%).
The optical rotation of 1 obtained by synthesis enabled the assignment of absolute configuration of 1. The enantiomer (+)-zuonin A (2) was also prepared in a similar manner starting from the enantiomer of 3,
In (−)-Zuonin A was initially discovered as an inhibitor of JNK through in silico screening. 26 We hypothesized that small molecules that bind the D-recruitment site (DRS) of JNK, a recruitment site utilized by substrates and other protein scaffolds to dock onto and recognize MAPKs, 39 would block the ability of JNK to efficiently engage protein ligands. To characterize the enantiomers of zuonin A, we first tested their ability to inhibit the phosphorylation of GST-c-Jun (2 μM) by activated JNK1, JNK2, and JNK3. As several kinetic studies of the JNKs have been reported, 40 we used these to guide the design of our kinetic investigations. First, we obtained dose− response curves for each enantiomer. (−)-Zuonin A exhibits IC 50 values in the range of 1.7−2.9 μM, plateauing at around 75% of the theoretical maximal level of inhibition when (−)-zuonin A is saturating (Table 1 (−)-Zuonin Inhibits the Activation of JNK1 by MKK4 and MKK7. JNK is activated by the dual-specificity kinases MKK4 and MKK7, which preferentially phosphorylate on Tyr-185 and Thr-183, respectively. 18 These kinases are reported to bind JNK within the DRS in a similar manner to the JIP scaffold and c-Jun protein substrate. 41 Thus, (−)-zuonin A is predicted to impede the binding of MKK4 and MKK7 to the inactive form of JNK. Indeed, we discovered that (−)-zuonin A does inhibit the phosphorylation of JNK1 by both kinases. Figure 3a shows a dose−response curve for the phosphorylation of JNK1 by MKK4 or MKK7 where the concentration of (−)-zuonin A was varied from 0 to 200 μM. These reveal values of IC 50 similar to those obtained with the active JNKs, and furthermore a submaximal level of inhibition is observed at saturating (−)-zuonin A, suggestive again of a partial-competitive inhibition mechanism. 42 as determined using an antiphospho-Ser-63 antibody, shows it is clearly blunted by the addition of (−)-zuonin A, but not by a DMSO control (Figure 1c) . Anisomycin has been reported to induce the appearance of two bands of phosphorylated c-Jun. 43 Migration from the lower band to the upper band has been suggested to be due to phosphorylation of Thr-91 and/or Thr-93, in addition to Ser-63 and Ser-73. 43 Interestingly, Figure with its decreased ability to inhibit the JNKs in the kinase assays (Figure 1a and b) .
Investigating JNK Self-Activation. (−)-Zuonin A Does Not Inhibit JNK2 Autoactivation. The JNK2 isoforms exhibit an ability to self-phosphorylate on the same residues phosphorylated by MKK4 and MKK7 both in vitro and in cells, leading to their activation. 19 Figure 3b shows that when overexpressed in HEK293T cells JNK2α2 becomes phosphorylated. As it is not known whether the DRS of JNK2α2 is important for autophosphorylation, we incubated cells with (−)-zuonin A and assessed the phosphorylation status of the overexpressed JNK2α2 by Western blot analysis. We found that (−)-zuonin A is unable to inhibit JNK2α2 autophosphorylation even at a concentration of 100 μM. In contrast, the phosphorylation of cJun, which is mediated by the overexpressed JNK2α2, is clearly blunted upon treatment of the cells with (−)-zuonin A with an ED 50 of approximately 25 μM (Figure 3b ). This provides strong evidence that (−)-zuonin A binds JNK2α2 in cells and impedes the interaction between JNK2α2 and c-Jun but does not prevent constitutive JNK2α2 phosphorylation resulting from the kinase binding ATP and phosphorylating itself. When the cells were treated with SP600125, 44 an inhibitor of JNK that binds within the ATP binding pocket of JNK2α2, its autophosphorylation was inhibited. However, when the cells were stimulated using anisomycin, SP600125 was no longer able to inhibit JNK2α2 phosphorylation, presumably because it was mediated by the activated MKK4 and MKK7 kinases (Figure 3c ). These observations are consistent with the proposed mechanisms of each inhibitor. Whereas (−)-zuonin A inhibits the binding of JNK2α2 to the upstream kinases and downstream substrates, it fails to prevent JNK2 from phosphorylating itself. In contrast, SP600125 prevents both JNK2α2 autophosphorylation and substrate phosphorylation but does not inhibit the ability of MKK4 and MKK7 to phosphorylate JNK2α2.
As noted above, (−)-zuonin A also impedes the phosphorylation of JNKs in cells following stimulation by anisomycin (Figure 1c) . While the ability of (−)-zuonin A to inhibit JNK phosphorylation in HEK293 cells might stem from its ability to impede the docking of MKK4 and MKK7 to JNK, it is also possible that other JNK-protein interactions are important. It is notable that the ED 50 for inhibiting JNK phosphorylation is around 25 μM, roughly 1 order of magnitude higher than the IC 50 value obtained in the kinase assays. Bioavailability may decrease the cellular potency of (−)-zuonin A compared to the in vitro kinase assay. It should be noted that the typical ED 50 for an ATP-competitive kinase inhibitor is in the micromolar range, reflecting the high concentration of competing MgATP in cells. For example SP600125 is an ATP-competitive inhibitor of JNK with an in vitro cell-free IC 50 of ∼40−100 nM, while its ED 50 for JNK activity in Jurkat T cells is ∼10 μM. 44 In this regard (−)-zuonin A may be regarded as a useful starting point for the development of more potent analogues. We conclude that (−)-zuonin A inhibits JNK by a protein-competitive mechanism where the competing protein is a JNK substrate, an upstream kinase or a scaffold. It remains to be determined how (−)-zuonin A affects the binding of other proteins, such as other substrates or the MAPK-specific phosphatases that dephosphorylate JNKs.
Inhibition of AKT Activation. JNK2α2 is reported to promote the tumorigenicity of human glioblastoma cells through Akt, whose activation is dependent on the presence of constitutively active JNK2 in U87MG cells. 12 ,45 Accordingly, we tested the effect of (−)-zuonin A and a DMSO control on Akt activation in HEK293T cells by monitoring Akt phosphorylation at Ser-473. 46 HEK293T cells were transfected with WT-JNK2α2 and treated with a DMSO control or different concentrations of (−)-zuonin A without induction by anisomycin. Interestingly, (−)-zuonin A was able to inhibit Akt phosphorylation mediated by JNK2α2 (Figure 3d) . Thus, (−)-zuonin A has potential as a modulator of Akt activity resulting from constitutive JNK2α2 activity.
Selectivity of (−)-Zuonin A against Other MAPKs in Cells. To profile the selectivity of (−)-zuonin A, we examined its ability to inhibit other MAP kinases, including ERK1, ERK2, p38MAPKα, p38MAPKβ, p38MAPKγ, and p38MAPKδ in kinase assays. (−)-Zuonin A showed little ability to inhibit any of these MAP kinases, supporting the notion that (−)-zuonin A is selective for the JNKs (Table 1) . This was further verified in HEK293T cells. For the p38 MAPK pathway, neither the phosphorylation of p38MAPK nor ATF2 (Activating Transcription Factor 2), a transcription factor substrate for the p38 MAP kinase, was affected after treatment of cells with 100 μM (−)-zuonin A (Figure 3f) . Similarly, 100 μM (−)-zuonin A had no effect on the phosphorylation of ERK or its protein substrate p-90RSK (Figure 3e ).
Chemical Genetics: Altering JNK Sensitivity to (−)-Zuonin A. In Vitro Studies. A binding mode for the binding of (−)-zuonin A to JNK was predicted using molecular dynamic simulation (Figure 4a ). The benzodioxole groups on (−)-zuonin A can potentially interact with both charged and nonpolar residues on JNK. The modeling suggests that one benzodioxole group may engage in π-stacking interactions with Tyr-130 and Trp-324 of JNK, with the other ring binding in the region of Asp-126, Arg-127, Cys-163, and Thr-164. We were interested in verifying the binding site of (−)-zuonin A and also wanted to identify residues whose mutation might compromise its binding. Accordingly, the following mutations, R127A, Y130A, C163A, T164A, W324A, and D326A, were incorporated individually into JNK2α2. Initially, we tested whether any of the mutants exhibited altered kinetic parameters using c-Jun as the protein substrate. Only the R127A mutant of JNK2α2 exhibited altered kinetic parameters for c-Jun phosphorylation, with the mutation resulting in an increase in the K m for c-Jun of 15-fold ( Table 2 ). As shown in Figure 4b and Table 2 , the C163A, R127A, and T164A mutants all exhibited an increased IC 50 , providing some support for the binding model. Interestingly, these mutations all resulted in a 2-fold decrease in the observed level of maximal inhibition at saturating (−)-zuonin A. In contrast, the Y130A and W324A mutants not only retained their ability to bind (−)-zuonin A but also displayed a shift in mechanism from partial to full inhibition (Table 2) . Thus, mutation of Tyr-130 or Trp-324 to alanine results in a mutant that phosphorylates c-Jun normally but is significantly more sensitive to (−)-zuonin A than wild type JNK2.
Cellular Studies. The C163A and Y130A mutants exhibited similar abilities to phosphorylate c-Jun, yet markedly different sensitivities to (−)-zuonin A, suggesting that they could be used in chemical genetic studies 47 to elucidate the role of JNK2 in cells. JNK2α2 (C163A) and JNK2α2 (Y130A) were transfected into HEK293T cells, which were subsequently treated with varied concentrations of (−)-zuonin A. Autophosphorylation of JNK2α2 and the subsequent phosphorylation of c-Jun were examined and compared to cells that were not transfected. The extent of phosphorylation of the JNK2 mutants was similar to exogenously expressed WT JNK2α2 in the absence of (−)-zuonin A (compare Figures 3b and 4c) . As expected, autophosphorylation of transfected and endogenous JNK was unaffected by (−)-zuonin A treatment ( Figure  4c ). However, a significant difference in the dose-dependence of c-Jun phosphorylation is evident between cells transfected with JNK2α2 (Y130A) and those transfected with JNK2α2 (C163A). Cells transfected with JNK2α2 Y130A are more sensitive to (−)-zuonin A than either those transfected with WT JNK2α2 or those not transfected at all. Strikingly, cells transfected with JNK2α2 (C163A) are unresponsive to (−)-zuonin A (Figures 3b and 4c) . While further studies are required to determine whether these mutations affect interactions between JNK and other proteins (e.g., other substrates) they hold promise as chemical-genetic tools to examine the function of JNK2 in cells.
(−)-Zuonin A Impedes Migration of Breast Cancer Cells. The invasion-metastatic cascade involves a series of events whereby tumor cells leave the primary tumor, intravasate into the circulation, extravasate at distant tissues, and establish micrometastases that may grow into macroscopic secondary tumors. 48 Cell migration is an early requirement for tumor metastasis, so inhibition of cell migration provides a potential strategy to inhibit metastasis. 49 The JNK pathway is known to play important roles in cell migration (e.g., ref 50) , and previously, we demonstrated an ability of a peptide that is selective for JNK2 to inhibit breast cancer cell migration. 16 Therefore, we examined whether (−)-zuonin A or (+)-zuonin A inhibited chemotactic cell migration of a highly metastatic human breast cancer cell line, namely, MDA-MB-231 in a (Table 1) and cell-based in vitro assays (Figures 1 and 5d) . However, the possibility of additional affects of (−)-zuonin A on cell migration, which are not attributable to JNK2, cannot be ruled out.
To summarize, we report the asymmetric synthesis of the lignans (−)-zuonin A and (+)-zuonin A and established the absolute configuration of the natural products. We show that (−)-zuonin A is a selective inhibitor of the JNKs and identify two mechanisms as likely contributors to its ability to inhibit JNK signaling in cells: (−)-zuonin A inhibits (i) JNK activation by MKK4 and MKK7 and (ii) substrate phosphorylation. In both cases it impedes the binding of the corresponding protein to the D-recruitment site of JNK. While (+)-zuonin A binds JNK, it is not an effective inhibitor. The activity of (−)-zuonin toward JNK is the basis for its ability to inhibit Akt signaling and breast cancer cell migration. Mutations in the predicted binding site for (−)-zuonin A can render it significantly more or less sensitive to inhibition than wild type JNK2, allowing for the design of potential chemical genetic experiments. These studies suggest that the biological activity reported for other lignans, such as saucerneol F and zuonin B, may be the result of blocking protein−protein interactions within MAPK cascades. These discoveries hold the potential to introduce future analogues into the arsenal of therapeutics now used to fight cancer cell metastasis.
■ METHODS
Cell culture, Western blot analysis, and cell migration assays are described in detail in the Supporting Information.
Kinase Activity Assay. MAP kinase assays were conducted as described in the Supporting Information.
Expression, Purification, and Activation of Tagless MAP Kinases, GST-ATF2 (1-115), GST-C-Jun (1-221), and His-Ets-1 (1-138). Different MAP kinases and protein substrates were expressed, purified, and then activated (if required) according to the methods described in the Supporting Information.
Molecular Dynamics Simulations. Molecular dynamics simulations for (−)-zuonin A bound to JNK are described in the Supporting Information.
Data Analysis. Steady-State Kinetic Experiments. Reactions were carried out as mentioned in the kinase activity assay except in the kinetic mechanism study, where we varied concentrations of substrate (c-Jun) and (−)-zuonin A. Initial rates were determined by linear leastsquares fitting to plots of product against time. Reciprocal plots of 1/v against 1/s were checked for linearity, before the data were fitted to eq 1 using a nonlinear least-squares approach, assuming equal variance for velocities, using the program Kaleidagraph 3.5 (Synergy software). Values for kinetic constants were then obtained using the program Sigma plot by fitting the kinetic data to the relevant overall equation. Data conforming to linear competitive inhibition were fitted to eq 2; data conforming to hyperbolic mixed inhibition were fitted to eq 3, which corresponds to an equation for partial competitive inhibition. Dose−response curves for data conforming to inhibition were fitted to eq 4. 
The parameters used in deriving equations are defined as follows; V 0 , observed rate; V max app , apparent maximum rate; s, concentration of substrate S; K mS app , apparent Michaelis constant for substrate S; i, concentration of inhibitor I; K i app or K ic app , apparent competitive inhibition constant for inhibitor I; αK i app , apparent uncompetitive inhibition constant for inhibitor I; βV max app , apparent maximum rate for enzyme inhibitor complex; V 00 , observed rate in the absence of inhibitor, V′, observed rate at saturating inhibitor I or activator x, K 50 , concentration that leads to half the maximal change in V 0 .
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